ICRmax: an optimized approach to detect tumor-specific interchromosomal rearrangements for clinical application. ICRMax and rectal tumor

We developed a computational pipeline (ICRmax) designed for the cost-effective identification of a minimal set of tumor-specific interchromosomal rearrangements (ICRs) for clinical application. We examined ICRmax performance on our own sequencing data derived from six rectal tumors achieving an average accuracy of 70% for ICR identification. ICRmax allows the identification of interchromosomal translocations from low-coverage (3x) sequenced tumor genomes, eliminates the need to sequence a matched normal tissue genome.